UnknownPHASE1, PHASE2NCT02864654
Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia
Studying Buerger disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
- Principal Investigator
- Andrey A Kalinin, MD, PhDFederal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation
- Intervention
- ADRC injection(procedure)
- Enrollment
- 9 enrolled
- Eligibility
- 50-85 years · All sexes
- Timeline
- 2016 – 2018
Study locations (1)
- Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation, Moscow, Russia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02864654 on ClinicalTrials.govOther trials for Buerger disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07215923A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy SmokersAntidote Therapeutics, Inc
- ENROLLING BY INVITATIONNCT07023965Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)Beijing Northland Biotech. Co., Ltd.
- RECRUITINGPHASE4NCT05854615Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's DiseaseCell Biopeutics Resources Sdn Bhd